Plus d\u2019un million de chirurgies cardiaques sont effectu\u00e9es annuellement, g\u00e9n\u00e9ralement avec succ\u00e8s. Pr\u00e8s du tiers des patients \u00e0 risque \u00e9lev\u00e9 conna\u00eetront toutefois une perte rapide de la fonction r\u00e9nale apr\u00e8s la chirurgie, ce qu\u2019on appelle une insuffisance r\u00e9nale aig\u00fce ou IRA. L\u2019IRA r\u00e9sulte d\u2019interruptions de br\u00e8ve dur\u00e9e du d\u00e9bit sanguin pendant la chirurgie; 11 % des patients qui ont une IRA apr\u00e8s un pontage d\u00e9c\u00e8deront, comparativement \u00e0 2 % chez ceux qui n\u2019en ont pas. Les patients qui survivent \u00e0 une IRA risquent de d\u00e9velopper des complications r\u00e9nales prolong\u00e9es comme une n\u00e9phropathie chronique ou une insuffisance r\u00e9nale chronique au stade ultime.<\/p>\n
Il est donc urgent de trouver de meilleurs moyens de pr\u00e9venir ou de traiter l\u2019IRA. M. Dumont et Van Slyke ont conceptualis\u00e9 et con\u00e7u un m\u00e9dicament appel\u00e9 Vasculotide (VT) qui se fixe au r\u00e9cepteur Tie2, responsable du maintien de la sant\u00e9 vasculaire (donc du d\u00e9bit sanguin). Vasomune Therapeutics, soci\u00e9t\u00e9 qui d\u00e9veloppe et commercialise le m\u00e9dicament, s\u2019associe \u00e0 Baxter International Inc., un chef de file mondial du march\u00e9 des soins r\u00e9naux, pour mettre au point le VT jusqu\u2019au point des essais cliniques chez des humains. \u00c0 ce moment\u00adl\u00e0, Vasomune sera en mesure de chercher du capital\u00adrisque pour poursuivre le d\u00e9veloppement.<\/p>\n
Dans les trois \u00e0 cinq ans qui suivront la fin du projet, Vasomune sera une soci\u00e9t\u00e9 ontarienne de biotechnologie dot\u00e9e de capital\u00adrisque pour le programme clinique de Phase II pour les maladies r\u00e9nales. La capacit\u00e9 de pr\u00e9venir ou de mettre fin \u00e0 l\u2019IRA fera \u00e9conomiser annuellement un milliard de dollars au syst\u00e8me de sant\u00e9, en partie parce que les patients seront moins nombreux \u00e0 d\u00e9velopper une maladie r\u00e9nale chronique. Les Canadiens auront aussi plus rapidement acc\u00e8s au VT. La commercialisation du VT assurera aussi des rendements financiers au Canada, de la formation et de la cr\u00e9ation d\u2019emplois pour le personnel hautement qualifi\u00e9.<\/p>\n","protected":false},"excerpt":{"rendered":"
Plus d\u2019un million de chirurgies cardiaques sont effectu\u00e9es annuellement, g\u00e9n\u00e9ralement avec succ\u00e8s. Pr\u00e8s du tiers des patients \u00e0 risque \u00e9lev\u00e9 conna\u00eetront toutefois une perte rapide de la fonction r\u00e9nale apr\u00e8s la chirurgie, ce qu\u2019on appelle une insuffisance r\u00e9nale aig\u00fce ou IRA. L\u2019IRA r\u00e9sulte d\u2019interruptions de br\u00e8ve dur\u00e9e du d\u00e9bit sanguin pendant la chirurgie; 11 % […]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"project-categories":[93],"genome-competitions":[210],"project-sector":[],"genome_centres":[108],"class_list":["post-10391","project","type-project","status-publish","hentry","project-categories-large-scale-science-fr","genome-competitions-programme-de-partenariats-pour-les-applications-de-la-genomique","genome_centres-ontario-genomics-fr"],"acf":[],"yoast_head":"\n